HIV treatment has transformed over the past decade, but affordability remains a major barrier for thousands of patients in New York. Tafero EM — the Indian WHO-GMP certified generic equivalent of Truvada and Descovy — provides the same clinical results at up to 98% lower cost.
Tafero EM contains Emtricitabine 200mg and Tenofovir Alafenamide 25mg (TAF), two nucleoside reverse transcriptase inhibitors (NRTIs) that together suppress HIV-1 viral replication and protect CD4 immune cells. The TAF formulation offers superior kidney and bone safety compared to older TDF-based medicines, making it suitable for long-term therapy.
For HIV-positive patients in New York, brand-name Descovy can cost over $1,800 per month without insurance. Tafero EM from India provides the same therapeutic benefit for a fraction of the price, making sustainable HIV management possible for uninsured and underinsured patients, hospital pharmacies, and community health clinics.
Tafero EM is also used in PrEP (Pre-Exposure Prophylaxis) protocols to prevent HIV transmission in high-risk individuals — a growing public health priority in New York City. Hospital pharmacies and HIV specialist clinics across the five boroughs are increasingly sourcing affordable Indian generics to meet patient demand.
Tafero EM contains Emtricitabine 200mg and Tenofovir Alafenamide 25mg (TAF), two nucleoside reverse transcriptase inhibitors (NRTIs) that together suppress HIV-1 viral replication and protect CD4 immune cells. The TAF formulation offers superior kidney and bone safety compared to older TDF-based medicines, making it suitable for long-term therapy.
For HIV-positive patients in New York, brand-name Descovy can cost over $1,800 per month without insurance. Tafero EM from India provides the same therapeutic benefit for a fraction of the price, making sustainable HIV management possible for uninsured and underinsured patients, hospital pharmacies, and community health clinics.
Tafero EM is also used in PrEP (Pre-Exposure Prophylaxis) protocols to prevent HIV transmission in high-risk individuals — a growing public health priority in New York City. Hospital pharmacies and HIV specialist clinics across the five boroughs are increasingly sourcing affordable Indian generics to meet patient demand.
